A Randomized, Double-blind, Placebo-Controlled Study of Sibutramine in the Treatment of Binge-Eating Disorder

Appolinário, José Carlos; Bacaltchuk, Josué; Sichieri, Rosely; Claudino, Angélica Medeiros; Godoy-Matos, Amélio F.; Morgan, Christina; Zanella, Maria Teresa; Coutinho, Walmir

doi:10.1001/archpsyc.60.11.1109

Cited by 174 publications

(113 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, topriamate was not found effective on depression and anxiety (15). Important decreases have been recorded in weight loss with sibutramin treatment (average 15 doses mg/day) (16). In the case we presented since the depressive symptoms were clear fluoxetine, as an antidepressant, was given.…”

Section: Discussionmentioning

confidence: 84%

Binge Eating Disorder and Obesity

Annagür

2011

ELECTRON J GEN MED

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 84%

Binge Eating Disorder and Obesity

Annagür

2011

ELECTRON J GEN MED

View full text Add to dashboard Cite

show abstract

“…110 In placebo-controlled studies (total n = 384), sibutramine (10-15 mg/day for 12-24 weeks) reduced body weight and the frequency of binge eating episodes more than placebo. [111][112][113] In one report, depression scores were also reduced more in the sibutramine group. 111 Finally, sibutramine was administered in a small group of obese adults with hypopituitary disease for 11 months.…”

Section: Therapeutic Use Of Sibutramine In Obesity-related Disordersmentioning

confidence: 93%

The use of sibutramine in the management of obesity and related disorders: An update

Tzotzas¹,

Krassas²,

Τζιόμαλος³

et al. 2009

VHRM

View full text Add to dashboard Cite

Aims:To review the major trials that evaluated the efficacy and safety of the use of sibutramine for weight loss and the impact of this agent on obesity-related disorders. Methods and results:The most important articles on sibutramine up to January 2009 were located by a PubMed and Medline search. Sibutramine reduces food intake and body weight more than placebo and has positive effects on the lipid profile (mainly triglycerides and high density lipoprotein cholesterol), glycemic control and inflammatory markers in studies for up to one year. Preliminary studies showed that sibutramine may also improve other obesityassociated disorders such as polycystic ovary syndrome, left ventricular hypertrophy, binge eating disorder and adolescent obesity. The high discontinuation rates and some safety issues mainly due to the increase in blood pressure and pulse rate have to be considered. Additionally, it has not yet been established that treatment with sibutramine will reduce cardiovascular events and total mortality. Conclusions: Sibutramine, in conjunction with lifestyle measures, is a useful drug for reducing body weight and improving associated cardiometabolic risk factors and obesity-related disorders. Studies of longer duration are required to determine the precise indications of the drug, to evaluate safety issues and to assess its efficacy on cardiovascular mortality.

show abstract

“…11,18 Positive therapeutic effects on both weight and binge eating have been reported with topiramate (antiepileptic), atomoxetine (norepinephrine reuptake inhibitor), sibutramine (mixed monoamine reuptake inhibitor causing anorexia and thermogenesis), the stimulant phentermine, selective serotonin reuptake inhibitors and rimonabant (cannabinoid receptor 1 inverse agonist). [19][20][21][22][23][24][25] However, safety concerns regarding psychiatric (rimonabant, topiramate) and cardiovascular risks (sibutramine, atomoxetine, phentermine) have hindered the clinical deployment of these treatments [26]. There is a need to explore novel pharmacological approaches, guided by the knowledge of the neurochemical systems implicated in the pathophysiology of abnormal eating.…”

Section: Introductionmentioning

confidence: 99%

Erratum: Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects

Ziauddeen¹,

Chamberlain²,

Nathan³

et al. 2014

Mol Psychiatry

View full text Add to dashboard Cite

The opioid system is implicated in the hedonic and motivational processing of food, and in binge eating, a behaviour strongly linked to obesity. The aim of this study was to evaluate the effects of 4 weeks of treatment with the mu-opioid receptor antagonist GSK1521498 on eating behaviour in binge-eating obese subjects. Adults with body mass index X30 kg m À 2 and binge eating scale scores X19 received 1-week single-blind placebo run-in, and were then randomized to 28 days with either 2 mg day À 1 GSK1521498, 5 mg day À 1 GSK1521498 or placebo (N ¼ 21 per arm) in a double-blind parallel group design. The outcome measures were body weight, fat mass, hedonic and consummatory eating behaviour during inpatient food challenges, safety and pharmacokinetics. The primary analysis was the comparison of change scores in the higher-dose treatment group versus placebo using analysis of covariance at each relevant time point. GSK1521498 (2 mg and 5 mg) was not different from placebo in its effects on weight, fat mass and binge eating scores. However, compared with placebo, GSK1521498 5 mg day À 1 caused a significant reduction in hedonic responses to sweetened dairy products and reduced calorific intake, particularly of high-fat foods during ad libitum buffet meals, with some of these effects correlating with systemic exposure of GSK1521498. There were no significant effects of GSK1521498 2 mg day À 1 on eating behaviour, indicating dose dependency of pharmacodynamics. GSK1521498 was generally well tolerated and no previously unidentified safety signals were detected. The potential for these findings to translate into clinically significant effects in the context of binge eating and weight regain prevention requires further investigation.

show abstract

A Randomized, Double-blind, Placebo-Controlled Study of Sibutramine in the Treatment of Binge-Eating Disorder

Abstract: Sibutramine is effective and well tolerated in the treatment of obese patients with BED. Its effects address 3 main domains of the BED syndrome, ie, binge eating, weight, and related depressive symptoms.

Cited by 174 publications

References 40 publications

Binge Eating Disorder and Obesity

Binge Eating Disorder and Obesity

The use of sibutramine in the management of obesity and related disorders: An update

Erratum: Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects

Contact Info

Product

Resources

About